Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report
Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Althou...
Saved in:
Published in | Journal of medical case reports Vol. 9; no. 217; p. 249 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
30.10.2015
BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Although extremely rare, fulminant liver damage related to infliximab therapy has been reported.
We present the case of a 38-year-old Afro-Brazilian woman with refractory ulcerative colitis who was started on infliximab. She had no previous history of liver disease, alcohol abuse, or infection. After the fifth dose of the medication, drug-induced liver injury was diagnosed. Treatment was discontinued but our patient's condition was aggravated by severe cholestasis and grade III/IV encephalopathy, requiring liver transplantation.
Drug-induced liver injury is an uncommon complication of infliximab. Current consensus recommends screening for liver dysfunction prior to and during therapy. This case emphasizes the need for vigilance and highlights a rare and potentially lethal complication. |
---|---|
AbstractList | Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Although extremely rare, fulminant liver damage related to infliximab therapy has been reported.
We present the case of a 38-year-old Afro-Brazilian woman with refractory ulcerative colitis who was started on infliximab. She had no previous history of liver disease, alcohol abuse, or infection. After the fifth dose of the medication, drug-induced liver injury was diagnosed. Treatment was discontinued but our patient's condition was aggravated by severe cholestasis and grade III/IV encephalopathy, requiring liver transplantation.
Drug-induced liver injury is an uncommon complication of infliximab. Current consensus recommends screening for liver dysfunction prior to and during therapy. This case emphasizes the need for vigilance and highlights a rare and potentially lethal complication. Introduction Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Although extremely rare, fulminant liver damage related to infliximab therapy has been reported. Case presentation We present the case of a 38-year-old Afro-Brazilian woman with refractory ulcerative colitis who was started on infliximab. She had no previous history of liver disease, alcohol abuse, or infection. After the fifth dose of the medication, drug-induced liver injury was diagnosed. Treatment was discontinued but our patient's condition was aggravated by severe cholestasis and grade III/IV encephalopathy, requiring liver transplantation. Conclusion Drug-induced liver injury is an uncommon complication of infliximab. Current consensus recommends screening for liver dysfunction prior to and during therapy. This case emphasizes the need for vigilance and highlights a rare and potentially lethal complication. Keywords: Hepatitis, Infliximab, Liver failure, Liver transplantation, Ulcerative colitis Antibodies against tumor necrosis factor alpha, such as infliximab (IFX), are increasingly being used to treat inflammatory bowel disease [1, 2]. They were originally used to manage moderate to severe active Crohn's disease but have recently been approved for severe ulcerative colitis (UC) [3]. The most worrisome adverse effects of IFX are the increased risks of developing serious infections and malignancies; therefore, close monitoring of patients is required to increase safety. Although uncommon, IFX therapy has been associated with drug-induced liver injury, which frequently occurs 13 weeks after its initiation but may be diagnosed up to 6 months later [4-11]. We report a rare case of severe UC treated with IFX that was complicated by fulminant hepatic failure and required urgent liver transplantation. INTRODUCTIONInfliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Although extremely rare, fulminant liver damage related to infliximab therapy has been reported.CASE PRESENTATIONWe present the case of a 38-year-old Afro-Brazilian woman with refractory ulcerative colitis who was started on infliximab. She had no previous history of liver disease, alcohol abuse, or infection. After the fifth dose of the medication, drug-induced liver injury was diagnosed. Treatment was discontinued but our patient's condition was aggravated by severe cholestasis and grade III/IV encephalopathy, requiring liver transplantation.CONCLUSIONDrug-induced liver injury is an uncommon complication of infliximab. Current consensus recommends screening for liver dysfunction prior to and during therapy. This case emphasizes the need for vigilance and highlights a rare and potentially lethal complication. Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Although extremely rare, fulminant liver damage related to infliximab therapy has been reported. Drug-induced liver injury is an uncommon complication of infliximab. Current consensus recommends screening for liver dysfunction prior to and during therapy. This case emphasizes the need for vigilance and highlights a rare and potentially lethal complication. |
ArticleNumber | 249 |
Audience | Academic |
Author | da Rocha, Jose Joaquim Ribeiro Feres, Omar Feitosa, Marley Ribeiro Parra, Rogerio Serafim Machado, Vanessa Foresto Ramalho, Leandra Naira Zambelli |
Author_xml | – sequence: 1 givenname: Rogerio Serafim surname: Parra fullname: Parra, Rogerio Serafim email: rogeriosparra@gmail.com organization: Division of Coloproctology, Department of Surgery and Anatomy, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, Zip: 14048-900, Brazil. rogeriosparra@gmail.com – sequence: 2 givenname: Marley Ribeiro surname: Feitosa fullname: Feitosa, Marley Ribeiro email: marleyfeitosa@yahoo.com.br organization: Division of Coloproctology, Department of Surgery and Anatomy, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, Zip: 14048-900, Brazil. marleyfeitosa@yahoo.com.br – sequence: 3 givenname: Vanessa Foresto surname: Machado fullname: Machado, Vanessa Foresto email: v_anfm@yahoo.com.br organization: Division of Coloproctology, Department of Surgery and Anatomy, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, Zip: 14048-900, Brazil. v_anfm@yahoo.com.br – sequence: 4 givenname: Leandra Naira Zambelli surname: Ramalho fullname: Ramalho, Leandra Naira Zambelli email: lramalho@fmrp.usp.br organization: Department of Pathology, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, Zip: 14048-900, Brazil. lramalho@fmrp.usp.br – sequence: 5 givenname: Jose Joaquim Ribeiro surname: da Rocha fullname: da Rocha, Jose Joaquim Ribeiro email: jjrocha1@bol.com.br organization: Division of Coloproctology, Department of Surgery and Anatomy, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, Zip: 14048-900, Brazil. jjrocha1@bol.com.br – sequence: 6 givenname: Omar surname: Feres fullname: Feres, Omar email: omar.feres@hspaulo.com.br organization: Division of Coloproctology, Department of Surgery and Anatomy, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, Zip: 14048-900, Brazil. omar.feres@hspaulo.com.br |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26518665$$D View this record in MEDLINE/PubMed |
BookMark | eNptkktr3DAUhUVJyav5Ad0UQ6F040Rv210EQugjEMgmXYtr-TqjIEtTyQ7tv6-GSdOZUrSQuPrOuVzpnJCDEAMS8pbRc8ZafZGZ4ErXlKmaNoLW6hU5Zo3iNetkc7BzPiInOT9SqnTbiUNyxLUqeq2Oyf1NGL376Sboa8g5WgczDtW4-MkFCHO1wjXMzlYjOL8krFyoFm8xleITVjZ6N7v8qYLKQsYq4Tqm-Q15PYLPePa8n5LvXz7fX3-rb---3lxf3dZWSqrqXnSc9YOQwHGkYlB9i6gQAVorOdMt73kveyE6bKBBPbCGAtMcW6Wo1Facksut73rpJxwshjmBN-tUxkm_TARn9m-CW5mH-GSk5k1pXgw-Phuk-GPBPJvJZYveQ8C4ZMMa3glFNRcFff8P-hiXFMp4hWo4p5K37V_qATwaF8ZY-tqNqbmSUqmWKaELdf4fqqwBJ2fLH4-u1PcEH3YEKwQ_r3L0y-xiyPsg24I2xZwTji-PwajZZMZsM2NKZswmM0YVzbvdV3xR_AmJ-A3Usrzf |
CitedBy_id | crossref_primary_10_1002_hep4_1465 crossref_primary_10_1016_j_mcna_2022_12_008 crossref_primary_10_1007_s10620_018_5023_6 crossref_primary_10_1097_MD_0000000000006156 crossref_primary_10_1097_MCG_0000000000001084 crossref_primary_10_1016_j_path_2018_02_009 crossref_primary_10_1016_j_aohep_2019_03_010 crossref_primary_10_1007_s40278_015_11182_4 crossref_primary_10_1177_24755303211047479 |
Cites_doi | 10.1016/j.crohns.2013.11.013 10.1016/j.cgh.2014.07.062 10.1002/ibd.20230 10.1111/j.1365-2036.2010.04435.x 10.3748/wjg.v20.i37.13234 10.7205/MILMED-D-14-00485 10.1111/tri.12185 10.4065/76.1.84 10.1053/j.gastro.2009.06.061 10.1007/s10067-005-0169-y 10.1016/j.cgh.2012.12.025 10.1016/j.cgh.2014.07.055 10.1016/j.crohns.2009.12.001 10.1007/s11739-009-0342-4 10.1016/j.crohns.2012.02.004 10.2165/00044011-200626110-00008 10.2165/11586290-000000000-00000 10.1159/000320410 10.1016/j.gtc.2014.05.008 10.1053/j.gastro.2011.06.054 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2015 BioMed Central Ltd. Copyright BioMed Central 2015 Parra et al. 2015 |
Copyright_xml | – notice: COPYRIGHT 2015 BioMed Central Ltd. – notice: Copyright BioMed Central 2015 – notice: Parra et al. 2015 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88C 88E 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M0T M1P NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1186/s13256-015-0730-5 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Proquest Nursing & Allied Health Source ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) ProQuest Healthcare Administration Database PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest - Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1752-1947 |
EndPage | 249 |
ExternalDocumentID | 3980106441 A445581536 10_1186_s13256_015_0730_5 26518665 |
Genre | Journal Article Case Reports |
GroupedDBID | --- -5E -5G -A0 -BR 0R~ 29L 2WC 3V. 4.4 53G 5GY 5VS 7RV 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACRMQ ADBBV ADINQ ADUKV AEAQA AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AQUVI BAPOH BAWUL BCNDV BENPR BFQNJ BKEYQ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK E3Z EBD EBLON EBS ECM EIF EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M0T M1P MK0 M~E NAPCQ NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP WOQ WOW AAYXX CITATION AFGXO 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c4405-b3921bd34a2ef03d5b8ee5eeaa8c421682b2b4b339e7a7e6d170a162e855046c3 |
IEDL.DBID | RPM |
ISSN | 1752-1947 |
IngestDate | Tue Sep 17 21:27:59 EDT 2024 Fri Aug 16 09:55:28 EDT 2024 Fri Sep 13 01:51:26 EDT 2024 Wed Aug 14 18:53:43 EDT 2024 Tue Aug 13 05:23:04 EDT 2024 Tue Aug 20 22:14:22 EDT 2024 Thu Sep 12 16:32:08 EDT 2024 Sat Sep 28 07:56:57 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 217 |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4405-b3921bd34a2ef03d5b8ee5eeaa8c421682b2b4b339e7a7e6d170a162e855046c3 |
Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627392/ |
PMID | 26518665 |
PQID | 1772204288 |
PQPubID | 2040215 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4627392 proquest_miscellaneous_1729350623 proquest_journals_1772204288 gale_infotracmisc_A445581536 gale_infotracacademiconefile_A445581536 gale_healthsolutions_A445581536 crossref_primary_10_1186_s13256_015_0730_5 pubmed_primary_26518665 |
PublicationCentury | 2000 |
PublicationDate | 2015-10-30 |
PublicationDateYYYYMMDD | 2015-10-30 |
PublicationDate_xml | – month: 10 year: 2015 text: 2015-10-30 day: 30 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of medical case reports |
PublicationTitleAlternate | J Med Case Rep |
PublicationYear | 2015 |
Publisher | BioMed Central Ltd BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
References | 19596014 - Gastroenterology. 2009 Oct;137(4):1250-60; quiz 1520 21175228 - BioDrugs. 2010 Dec 14;24 Suppl 1:3-14 21723220 - Gastroenterology. 2011 Oct;141(4):1194-201 25110253 - Gastroenterol Clin North Am. 2014 Sep;43(3):457-78 25117777 - Clin Gastroenterol Hepatol. 2015 Mar;13(3):531-8 25309060 - World J Gastroenterol. 2014 Oct 7;20(37):13234-8 26032391 - Mil Med. 2015 Jun;180(6):e723-4 20937043 - Aliment Pharmacol Ther. 2010 Oct;32(8):984-9 21122513 - J Crohns Colitis. 2010 Sep;4(3):221-56 24047326 - Transpl Int. 2013 Dec;26(12):e110-2 23333219 - Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3 25131534 - Clin Gastroenterol Hepatol. 2015 Mar;13(3):602-8 20107930 - Intern Emerg Med. 2010 Jun;5(3):193-200 17663423 - Inflamm Bowel Dis. 2007 Dec;13(12):1584-6 17163303 - Clin Drug Investig. 2006;26(11):673-6 22398069 - J Crohns Colitis. 2012 Jul;6(6):724-7 16547695 - Clin Rheumatol. 2007 Apr;26(4):578-81 20926880 - Dig Dis. 2010;28(3):508-18 24291019 - J Crohns Colitis. 2014 May;8(5):436-7 11155419 - Mayo Clin Proc. 2001 Jan;76(1):84-6 S Mancini (730_CR7) 2010; 5 GJ Tobon (730_CR5) 2007; 26 MT Arias (730_CR14) 2015; 13 BW Rowe (730_CR16) 2013; 26 ES Björnsson (730_CR4) 2015; 13 F Magro (730_CR1) 2010; 24 E Ierardi (730_CR8) 2006; 26 VV Menghini (730_CR6) 2001; 76 WJ Sandborn (730_CR12) 2009; 137 JF Colombel (730_CR13) 2011; 141 A Gustavsson (730_CR15) 2010; 32 730_CR9 S Singh (730_CR2) 2014; 43 W Miehsler (730_CR20) 2010; 4 GS Seo (730_CR3) 2014; 20 B Moum (730_CR10) 2007; 13 OS Khokhar (730_CR18) 2010; 28 M Ghabril (730_CR11) 2013; 11 U Kinnunen (730_CR17) 2012; 6 J Carvalheiro (730_CR19) 2014; 8 |
References_xml | – volume: 8 start-page: 436 issue: 5 year: 2014 ident: 730_CR19 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2013.11.013 contributor: fullname: J Carvalheiro – volume: 13 start-page: 602 issue: 3 year: 2015 ident: 730_CR4 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.07.062 contributor: fullname: ES Björnsson – volume: 13 start-page: 1584 year: 2007 ident: 730_CR10 publication-title: Inflamm Bowel Dis. doi: 10.1002/ibd.20230 contributor: fullname: B Moum – volume: 32 start-page: 984 issue: 8 year: 2010 ident: 730_CR15 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2010.04435.x contributor: fullname: A Gustavsson – volume: 20 start-page: 13234 issue: 37 year: 2014 ident: 730_CR3 publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i37.13234 contributor: fullname: GS Seo – ident: 730_CR9 doi: 10.7205/MILMED-D-14-00485 – volume: 26 start-page: e110 issue: 12 year: 2013 ident: 730_CR16 publication-title: Transpl Int doi: 10.1111/tri.12185 contributor: fullname: BW Rowe – volume: 76 start-page: 84 year: 2001 ident: 730_CR6 publication-title: Mayo Clin Proc. doi: 10.4065/76.1.84 contributor: fullname: VV Menghini – volume: 137 start-page: 1250 issue: 4 year: 2009 ident: 730_CR12 publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.06.061 contributor: fullname: WJ Sandborn – volume: 26 start-page: 578 issue: 4 year: 2007 ident: 730_CR5 publication-title: Clin Rheumatol doi: 10.1007/s10067-005-0169-y contributor: fullname: GJ Tobon – volume: 11 start-page: 558 issue: 5 year: 2013 ident: 730_CR11 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2012.12.025 contributor: fullname: M Ghabril – volume: 13 start-page: 531 issue: 3 year: 2015 ident: 730_CR14 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.07.055 contributor: fullname: MT Arias – volume: 4 start-page: 221 issue: 3 year: 2010 ident: 730_CR20 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2009.12.001 contributor: fullname: W Miehsler – volume: 5 start-page: 193 issue: 3 year: 2010 ident: 730_CR7 publication-title: Intern Emerg Med doi: 10.1007/s11739-009-0342-4 contributor: fullname: S Mancini – volume: 6 start-page: 724 issue: 6 year: 2012 ident: 730_CR17 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2012.02.004 contributor: fullname: U Kinnunen – volume: 26 start-page: 673 year: 2006 ident: 730_CR8 publication-title: Clin Drug Investig. doi: 10.2165/00044011-200626110-00008 contributor: fullname: E Ierardi – volume: 24 start-page: 3 issue: Suppl 1 year: 2010 ident: 730_CR1 publication-title: BioDrugs. doi: 10.2165/11586290-000000000-00000 contributor: fullname: F Magro – volume: 28 start-page: 508 issue: 3 year: 2010 ident: 730_CR18 publication-title: Dig Dis doi: 10.1159/000320410 contributor: fullname: OS Khokhar – volume: 43 start-page: 457 issue: 3 year: 2014 ident: 730_CR2 publication-title: Gastroenterol Clin North Am doi: 10.1016/j.gtc.2014.05.008 contributor: fullname: S Singh – volume: 141 start-page: 1194 issue: 4 year: 2011 ident: 730_CR13 publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.06.054 contributor: fullname: JF Colombel |
SSID | ssj0056893 |
Score | 2.1009994 |
Snippet | Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety.... Introduction Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and... Antibodies against tumor necrosis factor alpha, such as infliximab (IFX), are increasingly being used to treat inflammatory bowel disease [1, 2]. They were... INTRODUCTIONInfliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and... |
SourceID | pubmedcentral proquest gale crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 249 |
SubjectTerms | Adult Care and treatment Case Report Chemical and Drug Induced Liver Injury - pathology Chemical and Drug Induced Liver Injury - therapy Colitis, Ulcerative - drug therapy Complications and side effects Development and progression Disease Drug therapy Female Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - adverse effects Humans Infliximab Infliximab - administration & dosage Infliximab - adverse effects Liver diseases Liver Failure, Acute - chemically induced Liver Failure, Acute - therapy Liver Transplantation Medical treatment Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Ulcerative colitis |
SummonAdditionalLinks | – databaseName: ProQuest Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEB9qBfFFrJ-rrUYQBCHcJptkc75IKZZTqE8t9C3ka-lB3Wt7d-Cf78zu3tr1wefMhuxkMvNL5gvgo0QMbnTwPJlQcqohxW2VDM9lkh4NWtk0lJx89tMsLtSPS325B4tdLgyFVe50Yqeo0yrSG_lMIAyUBPDtzAd6BYib2debW079o8jPOjTTeAAPBYooNXGwJ2OwhzZolgefprBmtsY7mKabtOYk4lxPrNK_uvmecZoGTt6zRKdP4ckAIdlxv-cHsJfbZ_DobHCSP4fz75Tp8Xv5ywfuB-7nxJrtdR_2wq4yhVFH1vglBaWzZcu21zH3NcBZ7CLi1l-YZxFNHOu9Ci_g4vTb-cmCD80TeFQIwnhA4CNCqpSXuSmrpIPNWefsvY1KCmNlkEGFqprn2tfZJFGXXhiZqcKZMrF6Cfvtqs2vgSEk86ZMQeCEaq5qnFVkjbhRNjEELwr4vGOeu-lrZLjubmGN6zntkNOOOO10Ae-Jva5P8xzPlztWSmuL-tcU8KmjoBNG--yHRAFcDNWqmlAeTijxZMTp8G4L3XAy1-6vHBXwYRymLynarM2rLdEgCNIlIsMCXvU7Pv6YNLqrEVhAPZGFkYDqdU9H2uVVV7dbGcSKc_nm_8t6C48lCSbZx_IQ9jd323yEwGcT3nUy_QePpAHv priority: 102 providerName: ProQuest |
Title | Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26518665 https://www.proquest.com/docview/1772204288/abstract/ https://search.proquest.com/docview/1729350623 https://pubmed.ncbi.nlm.nih.gov/PMC4627392 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDsZexr7rrss0GAwGaixZkp29taGlG6SU0kLYi5BkmQYStywN9M_fnT9Cvce96EUnIZ_udHfW704AXyX64EZ7x0vjU041pHiRlYbHtJQODVpaVZScPLsw5zfq11zPd0D3uTANaD_4xVG9XB3Vi9sGW3m_CuMeJza-nE2VQaM7keNd2M2zrA_R2-NXG7TA3fWlKMx4jeGWpqBZc5JmTk_VSKObOm8DW_TvifzEJA3hkk_sz9kreNk5juy4XeBr2In1G3g-667G38L1T8rveFysnOeu43ksWbVZtmAXdhsJPB1Y5RYERWeLmm2WIbaVv1locHDrH8yxgIaNtXcJ7-Dm7PR6es67JxN4UOh6cY9sEb7MlJOxSrNS-yJGHaNzRVBSmEJ66ZXPsknMXR5NKfLUCSMj1TVTJmTvYa--q-M-MHTEnElLL3BCNVE5ziqiRm9RVsF7JxL43jPP3reVMWwTURTGtky3yHRLTLc6gc_EXtsmd261yh4rpXWBp65J4FtDQXqFXA6uSw_AxVCFqgHl4YAS9SEMu_sttJ0-rq3AIEJSeFgk8GXbTSMJY1bHuw3RoOujU_QHE_jQ7vj2w3qJSSAfyMKWgKp0D3tQeJtq3Z2wHvz3yI_wQpL4ksFMD2Hv4c8mfkJP6MGPUP7nObbFVIzg2cnpxeXVqPmrgO3Vye9Roxl_ARifDMM |
link.rule.ids | 230,315,733,786,790,870,891,12083,12250,21416,27957,27958,31754,31755,33301,33302,33779,33780,43345,43614,43840,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7aFNpcSt9xkzYqFAoFEUuWZG8uJYSGTZvNaQO5CUmWyULqTbJZ6M_vjK114x561ljIo3l80jwE8FkiBjfaO14bn3PqIcWrojY85rV06NDypqHi5Nm5mV6oH5f6Ml24rVJa5cYmdoa6Xga6Iz8QCAMlAfzq280tp1ejKLqantB4DE9UgY6GKsWPhxQPbdAZp0imqMzBCk9ems7PmpNgcz3yRf9a5AcuaZwu-cD_nLyA5wk4sqN-p1_Co9i-gqezFBp_DfNTqu_4vfjlPHeJ57Fmzfq6T3ZhV5GSpwNr3IJS0dmiZevrEPvO3yx0eXCrQ-ZYQMfG-ljCG7g4-T4_nvL0ZAIPCqEX9wh3hK8L5WRs8qLWvopRx-hcFZQUppJeeuWLYhJLV0ZTizJ3wshIfc2UCcVb2GqXbdwBhkDMmbz2AidUE1XirCJqRIuyCd47kcHXDfPsTd8Zw3YnisrYntMWOW2J01ZnsE_stX1x56BV9kgprSu0uiaDLx0F6RVyObhUHoCLoQ5VI8q9ESXqQxgPb7bQJn1c2b_Sk8GnYZi-pByzNi7XRIPQR-eIBzN41-_48GPS6K4zYAblSBYGAurSPR5pF1ddt25lECFO5Pv_L2sfnk3nszN7dnr-cxe2JQkpech8D7bu79bxA0Kfe_-xk-8_g78BJQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7aFEIvfT_cpo0KhUJBa1uWZG9vIe2StN2QQwKhFyHJMjHddZbuGkp_fUeWvaxzzFkjITEzmhn0zSeAjwxzcCmMpqU0CfUcUrTISkldUjKNAS2pKt-cPD-TJ5f8-5W42vnqqwPtW1NPmsVy0tTXHbZytbTxgBOLz-fHXGLQnbJ4VVbxfXiAPsumQ6EeLmEhMQ73j5hpIeM1Fl3Cl86Cepum_sMaJkXH9jaKSLfv5Z3ANAZN7kSh2WP4New_gE9-T9qNmdh_t6gd73TAJ_Coz03JURB5Cvdc8wz25_3r-3O4OPUtJH_rpTZU92p1JanaRcDTkGvn8dmWVLr2aHdSN6RdWBfIxYntoHbrL0QTi7GThOeKF3A5-3ZxfEL7Xxmo5ZjdUYMbS02Zcc1clWSlMIVzwjmtC8tZKgtmmOEmy6Yu17mTZZonOpXMeeo0Lm32Evaam8a9BoK5npZJaVJckE95jqumTmBCyiprjE4j-DxoRq0C-YbqipZCqqBRhRpVXqNKRHDodadC_-jWcdUR50IUeLHLCD51Et51UYVW9x0IuBlPgjWSPBhJosvZ8fBgH6p3-bVKsU5hvgItIviwHfYzPYytcTetl8HsSiSYckbwKpjT9mCDOUaQjwxtK-CJwMcjaD4dIXhvLm_uPPMQ9s-_ztTP07Mfb-Eh827iw3NyAHubP617h3nXxrzvPOw_BtEr6g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Infliximab-associated+fulminant+hepatic+failure+in+ulcerative+colitis%3A+a+case+report&rft.jtitle=Journal+of+medical+case+reports&rft.au=Parra%2C+Rogerio+Serafim&rft.au=Feitosa%2C+Marley+Ribeiro&rft.au=Machado%2C+Vanessa+Foresto&rft.au=Ramalho%2C+Leandra+Naira+Zambelli&rft.date=2015-10-30&rft.issn=1752-1947&rft.eissn=1752-1947&rft.volume=9&rft.issue=1&rft_id=info:doi/10.1186%2Fs13256-015-0730-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13256_015_0730_5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-1947&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-1947&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-1947&client=summon |